MedTrace Logo

Fulvestrant in Hormone Refractory Prostate Cancer

NCT00476645 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-08-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific antigen (PSA).

Conditions

Interventions

DRUG

Fulvestrant

Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly

Sponsors & Collaborators

Principal Investigators

  • Dr. Sandy Srinivas · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-09-30
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00476645 on ClinicalTrials.gov